(E)-Isovalencenol is a sesquiterpene alcohol strongly associated with vetiver root oil and appears repeatedly as one of its major odor-bearing markers. The best public evidence available here supports identity, occurrence, and whole-oil preclinical research rather than isolated-compound therapeutic data. Studies do place E-isovalencenol in vetiver oils and extracts that showed antimicrobial or anti-inflammatory style activity, but those results remain exploratory and should stay framed as composition context rather than medical evidence.
Chemical identity and composition
PubChem resolves E-isovalencenol as CID 6428372 with formula C15H24O, InChIKey FXWSXJNUPFBCMQ-GDULLBNJSA-N, and the name (E)-Eremophila-1(10),7(11)-dien-12-ol. NIST and SpectraBase align this stereochemical record with CAS 22387-74-2. Within the AromaForge archive, Haitian vetiver is reported at 14.62% (review table), Brazilian pharmacology work reported E-isovalencenol at 13.24% in the tested oil, and Indian or south-Indian profiles commonly place it in the mid-single to low-double-digit range.
Aroma and practical use
- Use the recorded woody, earthy, rooty, vetiver-like descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2012 full-text rodent study identified E-isovalencenol at 13.24% in Chrysopogon zizanioides essential oil and reported reduced writhing, reduced phase-2 formalin licking, and dose-dependent inhibition of carrageenan-related inflammatory models for the whole oil.
A 2012 full-text rodent study identified E-isovalencenol at 13.24% in Chrysopogon zizanioides essential oil and reported reduced writhing, reduced phase-2 formalin licking, and dose-dependent inhibition of carrageenan-related inflammatory models for the whole oil.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2025 vetiver review table listed (E)-isovalencenol at 14.62% in Haitian vetiver oil, supporting its importance as a major constituent in that origin profile.
A 2025 vetiver review table listed (E)-isovalencenol at 14.62% in Haitian vetiver oil, supporting its importance as a major constituent in that origin profile.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2010 lead-exposure study reported (E)-isovalencenol at 10.3-15.6% in vetiver oils produced under the tested cultivation conditions, again confirming it as a prominent constituent rather than a trace component.
A 2010 lead-exposure study reported (E)-isovalencenol at 10.3-15.6% in vetiver oils produced under the tested cultivation conditions, again confirming it as a prominent constituent rather than a trace component.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No authoritative constituent-specific IFRA restriction, inhalation limit, or human tolerability trial was verified for isolated E-isovalencenol in the reviewed public sources.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
The positive functional literature located in this pass is oil-level rather than isolated-compound evidence, so consumer-facing copy should avoid analgesic or anti-inflammatory claims for E-isovalencenol itself.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
major component in nonselective whole oil inflammation models
A full-text rodent paper reported anti-inflammatory and antinociceptive effects for vetiver essential oil containing 13.24% E-isovalencenol, but the mechanism was assigned at the whole-oil level and remained nonselective.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
chemotype quality marker
Across accessible GC-MS and review sources, E-isovalencenol functions most reliably as a vetiver chemotype and authenticity marker.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- No human clinical studies specific to isolated E-isovalencenol were verified in this pass.
- The reviewed pharmacology evidence is whole-oil rather than isolated-compound work, which limits mechanism claims.
- Public constituent-specific toxicology and dermal-limit data remain sparse.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.